Free Trial

Bioventix (LON:BVXP) Shares Cross Above 50-Day Moving Average - Here's What Happened

Bioventix logo with Medical background

Key Points

  • Bioventix PLC shares recently surpassed their 50-day moving average of GBX 2,766.48, reaching a high of GBX 2,800 during trading.
  • Corporate insider Bruce Hiscock purchased 31 shares at an average cost of GBX 2,632, indicating insider confidence in the stock.
  • Bioventix specializes in the creation and supply of sheep monoclonal antibodies (SMAs) for various diagnostic applications globally.
  • Five stocks we like better than Bioventix.
  • Limited Time Offer: Unlock powerful research tools, advanced financial data, and expert insights to help you invest with confidence. Save 50% when you upgrade to MarketBeat All Access during the month of July. Claim your discount here.

Bioventix PLC (LON:BVXP - Get Free Report) shares passed above its 50 day moving average during trading on Friday . The stock has a 50 day moving average of GBX 2,766.48 ($37.18) and traded as high as GBX 2,800 ($37.63). Bioventix shares last traded at GBX 2,720 ($36.55), with a volume of 3,977 shares.

Bioventix Trading Down 1.1%

The stock's fifty day moving average price is GBX 2,766.48 and its two-hundred day moving average price is GBX 2,795.73. The stock has a market capitalization of £142.43 million, a P/E ratio of 17.59 and a beta of 0.35.

Insider Buying and Selling

In other news, insider Bruce Hiscock purchased 31 shares of the stock in a transaction that occurred on Monday, April 28th. The stock was bought at an average cost of GBX 2,632 ($35.37) per share, for a total transaction of £815.92 ($1,096.52). 8.02% of the stock is owned by corporate insiders.

About Bioventix

(Get Free Report)

Bioventix PLC creates, manufactures, and supplies sheep monoclonal antibodies (SMAs) for diagnostic applications worldwide. The company offers a portfolio of purified SMAs for thyroid, vitamin D, cardiac, drugs of abuse, fertility, oncology, and miscellaneous indications; and Pyrene (HOP-G) ELISA kit to monitor human exposure to industrial pollutants.

Featured Articles

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Bioventix Right Now?

Before you consider Bioventix, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Bioventix wasn't on the list.

While Bioventix currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Analysts Agree—These Gold Picks Outshine the Rest Cover

Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

3 “Boring” Mega Cap Stocks to Turn Into Pure Profit
Joby vs. Archer: The $10 Billion eVTOL Battle
3 Small-Cap Biotech Stocks With Catalysts Too Big to Ignore

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines